ReviewCNS drugs2015
Targeting CGRP: A New Era for Migraine Treatment.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.European journal of medical research · 2022Pooled it
- Acupuncture modulates the abnormal brainstem activity in migraine without aura patients.NeuroImage. Clinical · 2017Trial
- Chemical multiplexing in the nervous system: molecular architecture, functional stratification, and pathophysiological plasticity of neuropeptide-classical neurotransmitter cotransmission.Frontiers in molecular neuroscience · 2026Review
- Persistence, switching, and healthcare use after initiating calcitonin gene-related peptide inhibitors: a real-world assessment.The journal of headache and pain · 2025Article
- Proteome-wide Mendelian randomization identified potential drug targets for migraine.The journal of headache and pain · 2024Article
- Antimigraine activity of Asarinin by OPRM1 pathway with multifaceted impacts through network analysis.Scientific reports · 2024Article
- Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine.The journal of headache and pain · 2024Article
- Potential analgesic effect of Foshousan oil-loaded chitosan-alginate nanoparticles on the treatment of migraine.Frontiers in pharmacology · 2023Article
- VDR Gene Polymorphisms and Cluster Headache Susceptibility: Case-Control Study in a Southeastern European Caucasian Population.Journal of molecular neuroscience : MN · 2022Article
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Migraine and Sleep-An Unexplained Association?International journal of molecular sciences · 2021Review
- Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison.Frontiers in pharmacology · 2021Review
- Migraine and prophylaxis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- In vitro affinity maturation of antibody against membrane-bound GPCR molecules.Applied microbiology and biotechnology · 2019Article
- Current and emerging evidence-based treatment options in chronic migraine: a narrative review.The journal of headache and pain · 2019Review
- The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.The journal of headache and pain · 2019Review
- Mouse Models of Familial Hemiplegic Migraine for Studying Migraine Pathophysiology.Current neuropharmacology · 2019Review
- Galcanezumab: First Global Approval.Drugs · 2018Review
- Review
- Fremanezumab for preventive treatment of migraine: Functional status on headache-free days.Neurology · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a highly prevalent headache disease that typically affects patients during their most productive years. Despite significant progress in understanding the underlying pathophysiology of this disorder, its treatment so far continues to depend on drugs that, in their majority, were not specifically designed for this purpose. The neuropeptide calcitonin gene-related peptide (CGRP) has been indicated as playing a critical role in the central and peripheral pathways leading to a migraine attack. It is not surprising that drugs designed to specifically block its action are gaining remarkable attention from researchers in the field with, at least so far, a safe risk profile. In this article, we highlight the evolution from older traditional treatments to the innovative CGRP target drugs that are revolutionizing the way to approach this debilitating neurological disease. We provide a brief introduction on pathophysiology of migraine and details on the characteristic, function, and localization of CGRP to then focus on CGRP receptor antagonists (CGRP-RAs) and CGRP monoclonal antibodies (CGRP mAbs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.